Home » Healthcare » Diabetic Nephropathy Market

Diabetic Nephropathy Market By Drug Class (ACE Inhibitors, ARBs (Angiotensin Receptor Blockers), SGLT2 Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Diuretics, Others (GLP-1, DPP-4, endothelin receptor antagonists, complement inhibitors)); By Diabetes Type (Type 1 Diabetes, Type 2 Diabetes); By End-User (Hospital Pharmacies, Retail Pharmacies, Online Providers, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Diabetic Nephropathy Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-09-23
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Diabetic Nephropathy Market

Summary
Table Of Content
Request Free Sample

Market Overview:

Diabetic Nephropathy market size was valued at USD 2,150.00 million in 2018, reaching USD 2,670.72 million in 2024, and is anticipated to reach USD 4,281.59 million by 2032, at a CAGR of 6.10% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Diabetic Nephropathy Market Size 2024	USD 2,670.72 million
Diabetic Nephropathy Market, CAGR	6.10%
Diabetic Nephropathy Market Size 2032	USD 4,281.59 million

The diabetic nephropathy market is led by major pharmaceutical players including Novartis AG, AstraZeneca PLC, Sanofi, Bayer AG, Merck & Co., Inc., and Pfizer Inc., supported by key contributors such as AbbVie, Eli Lilly, Teva Pharmaceutical Industries Ltd., and Johnson & Johnson. These companies focus on renoprotective therapies, including ACE inhibitors, ARBs, and innovative SGLT2 inhibitors, alongside active clinical trials for new drug classes. North America dominated the market in 2024 with 38.3% share, driven by strong healthcare infrastructure and high therapy adoption, followed by Europe with 28.7% share. Asia Pacific emerged as the fastest-growing region, supported by rising diabetes prevalence, expanding healthcare access, and growing generic drug availability, making it a critical growth hub through 2032.

Diabetic Nephropathy Market size

Market Insights

The diabetic nephropathy market was valued at USD 2,670.72 million in 2024 and is projected to reach USD 4,281.59 million by 2032, growing at a 6.10% CAGR.
Rising diabetes prevalence, early screening programs, and adoption of renoprotective therapies such as ACE inhibitors and SGLT2 inhibitors are major drivers boosting market growth.
Key trends include early initiation of combination therapies, growing use of personalized medicine, and digital health platforms improving treatment adherence and outcomes.
The market is competitive with top players like Novartis, AstraZeneca, Sanofi, Bayer, Merck, and Pfizer leading through innovation, clinical trials, and partnerships, while generic manufacturers expand affordability.
North America leads with 38.3% share, followed by Europe at 28.7%, while Asia Pacific is the fastest-growing region at 7.9% CAGR. By drug class, ACE inhibitors dominate with over 35% share, and Type 2 diabetes accounts for more than 70% of total revenue.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Segmentation Analysis:

By Drug Class

ACE inhibitors dominated the diabetic nephropathy market in 2024, holding over 35% market share. Their leadership is driven by proven efficacy in reducing intraglomerular pressure, slowing disease progression, and lowering proteinuria in early-stage nephropathy. ARBs closely follow, preferred for patient’s intolerant to ACE inhibitors, while SGLT2 inhibitors are gaining momentum due to kidney-protective benefits beyond glucose control. MRAs and diuretics remain supportive therapies for blood pressure and fluid management. The “Others” category, including GLP-1 and endothelin receptor antagonists, is expanding, driven by clinical trials showcasing additive renal protection and reduced cardiovascular risk.

For instance, Zestril (lisinopril), with documented clinical evidence of renal protection in early-stage nephropathy, was prescribed in many patient courses globally in 2024. While its former manufacturer, AstraZeneca, sold most of the global rights to the brand in 2020, lisinopril continues to be widely used, both as Zestril and as a generic medication.

By Diabetes Type

Type 2 diabetes accounted for over 70% of market revenue in 2024, making it the dominant segment. The high prevalence of type 2 diabetes globally, particularly in aging populations, drives this dominance. Rising obesity rates, sedentary lifestyles, and increasing awareness of early screening programs contribute to higher diagnosis rates. Type 1 diabetes represents a smaller but stable share, with growing adoption of renoprotective therapies and continuous glucose monitoring solutions improving treatment adherence. Expansion of targeted therapies and personalized treatment approaches is expected to further strengthen the type 2 segment during the forecast period.

For instance, Novo Nordisk’s Ozempic (semaglutide) reached more than 4.8 million patients in 2024, contributing to early glycemic control and delaying renal complications.

By End-User

Hospital pharmacies led the market with nearly 50% share in 2024, supported by strong prescription volumes for acute and chronic care management. Their dominance is attributed to physician-driven prescribing patterns and availability of a full range of drug classes, including injectables and specialty therapies. Retail pharmacies follow, benefiting from patient convenience and long-term therapy refills. Online providers are growing rapidly, fueled by telemedicine adoption, e-pharmacy platforms, and home delivery services. The “Others” category, including specialty clinics, contributes steadily, supported by integrated care programs and chronic kidney disease management initiatives.

Market Overview

Rising Global Diabetes Prevalence

The growing incidence of diabetes remains the primary driver for diabetic nephropathy market growth. According to international health bodies, over 500 million people live with diabetes globally, with Type 2 diabetes forming the majority. This rapid rise has increased the patient pool at risk for kidney complications. Early screening programs and routine albuminuria testing are leading to higher diagnosis rates. Governments and NGOs are also running awareness campaigns about chronic kidney disease, driving early intervention and treatment uptake. As a result, demand for renoprotective therapies such as ACE inhibitors, ARBs, and SGLT2 inhibitors continues to expand steadily across both developed and emerging markets.

For instance, in 2024, Abbott’s FreeStyle Libre CGM devices were used by approximately 6 million people globally. By helping users monitor and control their glucose levels, the technology can assist in managing diabetes, which is a major risk factor for developing kidney disease.

Advancements in Renoprotective Therapies

Innovative drugs targeting kidney function preservation have significantly changed treatment approaches. SGLT2 inhibitors and non-steroidal MRAs are increasingly prescribed due to their ability to reduce albuminuria and slow progression to end-stage renal disease. Clinical studies show combination therapy with ACE inhibitors or ARBs further improves renal outcomes. Pipeline developments include endothelin receptor antagonists and complement inhibitors with promising Phase III results. These innovations are attracting strong investments from leading pharmaceutical companies and expanding treatment options for patients. Improved clinical guidelines recommending early use of these therapies are driving adoption across primary care and specialist practices.

For instance, Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) showed a 28% reduction in kidney disease progression in the EMPA-KIDNEY trial with 6,609 participants.

Increasing Access to Healthcare and Digital Health Platforms

Rising healthcare expenditure and the expansion of reimbursement coverage for chronic kidney disease therapies are improving treatment accessibility. Telemedicine services and online pharmacy platforms make it easier for patients to consult nephrologists and receive prescriptions without hospital visits. This shift is particularly relevant for rural populations and elderly patients with mobility challenges. Governments are investing in kidney health programs and subsidizing dialysis services, which indirectly boost early pharmacological interventions. Digital platforms offering medication reminders and adherence tracking are further enhancing patient compliance, leading to better health outcomes and consistent demand for diabetic nephropathy drugs.

Key Trends & Opportunities

Shift Toward Combination and Early Therapy

Treatment strategies are moving toward initiating therapy early in the disease course to prevent irreversible damage. Combination therapies using SGLT2 inhibitors with ACE inhibitors or ARBs are being adopted widely, supported by positive clinical evidence. Pharmaceutical companies are investing in fixed-dose combinations to improve compliance and simplify therapy regimens. This trend presents opportunities for drug developers to capture market share with differentiated products and expand into preventive therapy segments, delaying progression to dialysis or transplantation.

For instance, the EMPA-KIDNEY trial with 6,609 participants demonstrated that empagliflozin combined with ACE inhibitor therapy significantly reduced the risk of kidney failure and cardiovascular events.

Emergence of Personalized Medicine and Biomarker-Based Treatment

Advances in genomics and biomarker research are enabling more targeted treatment approaches for diabetic nephropathy. Predictive biomarkers are being used to stratify patients based on disease risk and therapy response. This creates opportunities for precision medicine solutions that improve efficacy and reduce adverse effects. Companies developing companion diagnostics alongside novel drug candidates stand to benefit from this trend. Personalized therapy also aligns with value-based healthcare models, where payers increasingly prefer treatments that demonstrate measurable improvements in outcomes.

Key Challenges

High Treatment Costs and Limited Affordability

The cost of advanced therapies, particularly novel SGLT2 inhibitors and MRAs, remains a barrier in many low- and middle-income countries. Out-of-pocket expenses deter patients from long-term adherence, leading to suboptimal outcomes and increased progression to dialysis. Limited reimbursement coverage in certain regions further restricts access to innovative drugs. Pharmaceutical companies face pressure to introduce cost-effective generics and patient assistance programs to make therapies more affordable and drive wider adoption.

Low Diagnosis and Late-Stage Detection Rates

Many patients are diagnosed with diabetic nephropathy at advanced stages, where kidney damage is irreversible, limiting the benefits of drug therapy. Lack of awareness about routine kidney screening and limited access to diagnostic facilities in rural areas contribute to this challenge. Late detection increases healthcare costs and burden on dialysis centers. Expanding screening programs, integrating kidney tests into routine diabetes care, and educating primary care physicians are critical steps to address this issue and capture untreated patient segments earlier.

Regional Analysis

North America

North America led the diabetic nephropathy market in 2024 with 38.3% share, valued at USD 1,023.14 million, up from USD 833.13 million in 2018. The market is projected to reach USD 1,638.15 million by 2032, growing at a 6.1% CAGR. Strong healthcare infrastructure, high diabetes prevalence, and widespread access to renoprotective therapies support its dominance. Favorable reimbursement policies, rising adoption of SGLT2 inhibitors, and early screening programs further drive regional growth. The U.S. remains the largest contributor, supported by robust R&D investments, innovative drug launches, and initiatives promoting early detection and management of chronic kidney disease.

Europe

Europe accounted for 28.7% of market share in 2024, with a value of USD 765.89 million, rising from USD 638.55 million in 2018. The market is expected to reach USD 1,167.82 million by 2032 at a 5.4% CAGR. Growth is supported by universal healthcare coverage, strong physician awareness, and guidelines recommending ACE inhibitors and ARBs for early intervention. Western European countries such as Germany, France, and the UK dominate revenue contribution. Expanding use of SGLT2 inhibitors and increasing patient participation in kidney health programs enhance treatment penetration across the region, boosting adoption of advanced nephropathy therapies.

Asia Pacific

Asia Pacific is the fastest-growing market, projected to expand at a 7.9% CAGR to reach USD 908.99 million by 2032, from USD 496.34 million in 2024 and USD 376.25 million in 2018. The region represented 18.6% of global share in 2024, supported by a rapidly growing diabetic population, particularly in China and India. Rising healthcare spending, growing awareness of chronic kidney disease, and expansion of dialysis and specialty care centers drive market expansion. Government initiatives promoting diabetes management and the adoption of cost-effective generics strengthen accessibility, making Asia Pacific a key growth engine for the forecast period.

Latin America

Latin America held 7.8% market share in 2024, valued at USD 206.69 million, up from USD 167.70 million in 2018. The market is forecast to reach USD 312.00 million by 2032, expanding at a 5.3% CAGR. Increasing prevalence of obesity and diabetes, particularly in Brazil and Mexico, is boosting demand for early nephropathy treatment. Government health programs focusing on non-communicable disease management and improving access to essential medicines support market growth. Expansion of private healthcare infrastructure and availability of affordable generics further enhance treatment coverage, making the region an attractive opportunity for pharmaceutical companies.

Middle East

The Middle East accounted for 3.9% of the global market in 2024, with a value of USD 103.61 million, rising from USD 88.58 million in 2018. The market is anticipated to reach USD 151.16 million by 2032, growing at a 4.9% CAGR. Rising rates of type 2 diabetes due to lifestyle changes and urbanization are increasing nephropathy cases. Investments in specialty clinics and diagnostic infrastructure are improving early detection rates. Countries like Saudi Arabia and the UAE are leading growth due to better healthcare access and government initiatives promoting chronic disease screening and patient education.

Africa

Africa represented 2.8% market share in 2024, valued at USD 75.06 million, up from USD 45.80 million in 2018. The market is projected to reach USD 103.48 million by 2032, growing at a 3.7% CAGR, the slowest among regions. Limited healthcare infrastructure, low awareness, and delayed diagnosis remain major challenges, restricting early treatment uptake. However, international health programs and NGO-led initiatives are increasing access to diabetes management solutions. Gradual improvements in healthcare funding and availability of cost-effective therapies are expected to drive moderate growth, especially in urban centers across South Africa, Nigeria, and Kenya.

Market Segmentations:

By Drug Class

ACE Inhibitors
ARBs (Angiotensin Receptor Blockers)
SGLT2 Inhibitors
Mineralocorticoid Receptor Antagonists (MRAs)
Diuretics
Others (GLP-1, DPP-4, endothelin receptor antagonists, complement inhibitors)

By Diabetes Type

Type 1 Diabetes
Type 2 Diabetes

By End-User

Hospital Pharmacies
Retail Pharmacies
Online Providers
Others

By Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Competitive Landscape

The diabetic nephropathy market is highly competitive, with leading players focusing on innovation and strategic collaborations to strengthen their market presence. Major companies such as Novartis AG, AstraZeneca PLC, Sanofi, Bayer AG, Merck & Co., Inc., and Pfizer Inc. dominate with extensive portfolios of ACE inhibitors, ARBs, and novel SGLT2 inhibitors. These firms invest heavily in R&D to advance renoprotective therapies and launch combination treatments that improve patient outcomes. Emerging players like Reata Pharmaceuticals, Inc. are introducing first-in-class drugs targeting new pathways, intensifying competition. Strategic alliances, acquisitions, and licensing agreements are common strategies to expand geographic reach and access to new technologies. Additionally, companies are leveraging digital health platforms to improve adherence and patient engagement. The presence of generic drug manufacturers such as Teva Pharmaceutical Industries Ltd. and Aurobindo Pharma Limited further increases market competitiveness by offering affordable alternatives, enhancing treatment accessibility across emerging and price-sensitive markets.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novartis AG
AstraZeneca PLC
Sanofi
Bayer AG
Merck & Co., Inc.
Pfizer Inc.
AbbVie, Inc.
Eli Lilly and Company
Aurobindo Pharma Limited
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
Reata Pharmaceuticals, Inc.

Recent Developments

In November 2024, Thiruvananthapuram launched a year-long diabetes action plan, trained doctors and health workers, and hosted an international seminar in January 2025.
In May 2024, AstraZeneca developed a new app for primary care physicians to manage chronic kidney disease (CKD) and predict kidney failure risk, partnering with various medical organizations to promote early detection and intervention.
In February 2024, Simple HealthKit introduced a kidney disease testing program to improve health plans’ performance, focusing on hard-to-reach members and HEDIS and Medicare Advantage star ratings.
In November 2023, ProKidney Corp. obtained approval from the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and received scientific advice from the EMA regarding phase 3 protocols for REACT in diabetic chronic kidney disease.
In September 2023, the U.S. FDA approved Jardiance, a 10mg tablet, to reduce kidney disease progression and cardiovascular death in CKD patients, but not those with type 1 diabetes, polycystic kidney disease, immunosuppressive therapy, or empagliflozin hypersensitivity.

Report Coverage

The research report offers an in-depth analysis based on Drug Class, Diabetes Type, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The market will grow steadily driven by rising global diabetes prevalence and aging populations.
Adoption of SGLT2 inhibitors and MRAs will expand as first-line renoprotective therapies.
Combination therapy use will increase to improve outcomes and delay kidney disease progression.
Biomarker-based patient stratification will support personalized treatment approaches.
Telemedicine and e-pharmacy growth will improve access and adherence for chronic care patients.
Pharmaceutical companies will invest more in R&D for novel targets like endothelin and complement pathways.
Partnerships between drug makers and digital health platforms will enhance patient monitoring.
Emerging markets will see higher penetration due to improved healthcare infrastructure and generics availability.
Competitive pressure will rise as more biosimilars and cost-effective alternatives enter the market.
Early detection programs and government initiatives will reduce late-stage diagnosis and drive therapy uptake.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : DIABETIC NEPHROPATHY MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by product

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Diabetes Type Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Drug Class & Diabetes Type Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Diabetic Nephropathy Market Import Revenue By Region

6.2. Export Analysis by Region

6.2.1. Global Diabetic Nephropathy Market Export Revenue By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Diabetic Nephropathy Market: Company Market Share

7.2. Global Diabetic Nephropathy Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : DIABETIC NEPHROPATHY MARKET – BY DRUG CLASS SEGMENT ANALYSIS

8.1. Diabetic Nephropathy Market Overview by Drug Class Segment

8.1.1. Diabetic Nephropathy Market Revenue Share By Drug Class

8.2. ACE Inhibitors

8.3. ARBs (Angiotensin Receptor Blockers)

8.4. SGLT2 Inhibitors

8.5. Mineralocorticoid Receptor Antagonists (MRAs)

8.6. Diuretics

8.7. Others (GLP‑1, DPP‑4, endothelin receptor antagonists, complement inhibitors)

CHAPTER NO. 9 : DIABETIC NEPHROPATHY MARKET – BY DIABETES TYPE SEGMENT ANALYSIS

9.1. Diabetic Nephropathy Market Overview by Diabetes Type Segment

9.1.1. Diabetic Nephropathy Market Revenue Share By Diabetes Type

9.2. Type 1 Diabetes

9.3. Type 2 Diabetes

CHAPTER NO. 10 : DIABETIC NEPHROPATHY MARKET – BY END-USER SEGMENT ANALYSIS

10.1. Diabetic Nephropathy Market Overview by End-user Segment

10.1.1. Diabetic Nephropathy Market Revenue Share By End-user

10.2. Hospital Pharmacies

10.3. Retail Pharmacies

10.4. Online Providers

10.5. Others

CHAPTER NO. 11 : DIABETIC NEPHROPATHY MARKET – REGIONAL ANALYSIS

11.1. Diabetic Nephropathy Market Overview by Region Segment

11.1.1. Global Diabetic Nephropathy Market Revenue Share By Region

11.1.3. Regions

11.1.4. Global Diabetic Nephropathy Market Revenue By Region

.1.6. Drug Class

11.1.7. Global Diabetic Nephropathy Market Revenue By Drug Class

11.1.9. Diabetes Type

11.1.10. Global Diabetic Nephropathy Market Revenue By Diabetes Type

11.1.12. End-user

11.1.13. Global Diabetic Nephropathy Market Revenue By End-user

CHAPTER NO. 12 : NORTH AMERICA DIABETIC NEPHROPATHY MARKET – COUNTRY ANALYSIS

12.1. North America Diabetic Nephropathy Market Overview by Country Segment

12.1.1. North America Diabetic Nephropathy Market Revenue Share By Region

12.2. North America

12.2.1. North America Diabetic Nephropathy Market Revenue By Country

12.2.2. Drug Class

12.2.3. North America Diabetic Nephropathy Market Revenue By Drug Class

12.2.4. Diabetes Type

12.2.5. North America Diabetic Nephropathy Market Revenue By Diabetes Type

2.2.6. End-user

12.2.7. North America Diabetic Nephropathy Market Revenue By End-user

2.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13 : EUROPE DIABETIC NEPHROPATHY MARKET – COUNTRY ANALYSIS

13.1. Europe Diabetic Nephropathy Market Overview by Country Segment

13.1.1. Europe Diabetic Nephropathy Market Revenue Share By Region

13.2. Europe

13.2.1. Europe Diabetic Nephropathy Market Revenue By Country

13.2.2. Drug Class

13.2.3. Europe Diabetic Nephropathy Market Revenue By Drug Class

13.2.4. Diabetes Type

13.2.5. Europe Diabetic Nephropathy Market Revenue By Diabetes Type

13.2.6. End-user

13.2.7. Europe Diabetic Nephropathy Market Revenue By End-user

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC DIABETIC NEPHROPATHY MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Diabetic Nephropathy Market Overview by Country Segment

14.1.1. Asia Pacific Diabetic Nephropathy Market Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Diabetic Nephropathy Market Revenue By Country

14.2.2. Drug Class

14.2.3. Asia Pacific Diabetic Nephropathy Market Revenue By Drug Class

14.2.4. Diabetes Type

14.2.5. Asia Pacific Diabetic Nephropathy Market Revenue By Diabetes Type

14.2.5. End-user

14.2.7. Asia Pacific Diabetic Nephropathy Market Revenue By End-user

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA DIABETIC NEPHROPATHY MARKET – COUNTRY ANALYSIS

15.1. Latin America Diabetic Nephropathy Market Overview by Country Segment

15.1.1. Latin America Diabetic Nephropathy Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Diabetic Nephropathy Market Revenue By Country

15.2.2. Drug Class

15.2.3. Latin America Diabetic Nephropathy Market Revenue By Drug Class

15.2.4. Diabetes Type

15.2.5. Latin America Diabetic Nephropathy Market Revenue By Diabetes Type

15.2.6. End-user

15.2.7. Latin America Diabetic Nephropathy Market Revenue By End-user

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST DIABETIC NEPHROPATHY MARKET – COUNTRY ANALYSIS

16.1. Middle East Diabetic Nephropathy Market Overview by Country Segment

16.1.1. Middle East Diabetic Nephropathy Market Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Diabetic Nephropathy Market Revenue By Country

16.2.2. Drug Class

16.2.3. Middle East Diabetic Nephropathy Market Revenue By Drug Class

16.2.4. Diabetes Type

16.2.5. Middle East Diabetic Nephropathy Market Revenue By Diabetes Type

16.2.6. End-user

16.2.7. Middle East Diabetic Nephropathy Market Revenue By End-user

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17 : AFRICA DIABETIC NEPHROPATHY MARKET – COUNTRY ANALYSIS

17.1. Africa Diabetic Nephropathy Market Overview by Country Segment

17.1.1. Africa Diabetic Nephropathy Market Revenue Share By Region

17.2. Africa

17.2.1. Africa Diabetic Nephropathy Market Revenue By Country

17.2.2. Drug Class

17.2.3. Africa Diabetic Nephropathy Market Revenue By Drug Class

17.2.4. Diabetes Type

17.2.5. Africa Diabetic Nephropathy Market Revenue By Diabetes Type

17.2.6. End-user

17.2.7. Africa Diabetic Nephropathy Market Revenue By End-user

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18 : COMPANY PROFILES

18.1. Novartis AG

18.1.1. Company Overview

18.1.2. Product Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. AstraZeneca PLC

18.3. Sanofi

18.4. Bayer AG

18.5. Merck & Co., Inc.

18.6. Pfizer Inc.

18.7. AbbVie, Inc.

18.8. Eli Lilly and Company

18.9. Aurobindo Pharma Limited

18.10. Sun Pharmaceutical Industries Ltd.

18.11. Teva Pharmaceutical Industries Ltd.

18.12. Johnson & Johnson Services, Inc.

18.13. Bristol‑Myers Squibb Company

18.14. Reata Pharmaceuticals, Inc.

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions

What is the current market size for Diabetic Nephropathy market, and what is its projected size in 2032?

The market was valued at USD 2,670.72 million in 2024 and is projected to reach USD 4,281.59 million by 2032.

At what Compound Annual Growth Rate is the Diabetic Nephropathy market projected to grow between 2025 and 2032?

The market is expected to grow at a CAGR of 6.10% during 2025–2032.

Which Diabetic Nephropathy market segment held the largest share in 2024?

ACE inhibitors led the market in 2024, accounting for over 35% share.

What are the primary factors fueling the growth of the Diabetic Nephropathy market?

Rising diabetes prevalence, early screening programs, and adoption of renoprotective therapies such as ACE inhibitors and SGLT2 inhibitors are key growth drivers.

Who are the leading companies in the Diabetic Nephropathy market?

Major players include Novartis AG, AstraZeneca PLC, Sanofi, Bayer AG, Merck & Co., Inc., and Pfizer Inc.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

Sperm Count Test Market

Sperm Count Test Market size was valued USD 2.32 billion in 2024 and is anticipated to reach USD 3.79 billion by 2032, at a CAGR of 6.3% during the forecast period.

Specialty Pharmaceuticals Market

The Specialty Pharmaceuticals Market size was valued at USD 225.73 billion in 2024 and is anticipated to reach USD 1461.55 billion by 2032, at a CAGR of 26.3% during the forecast period (2024-2032).

PET Packaging In Pharmaceutical Market

The PET packaging in pharmaceutical market was valued at USD 7,498.00 million in 2024 and is projected to reach USD 11,162.65 million by 2032, growing at a CAGR of 5.1% during the forecast period.

Whole Genome Sequencing Market

Whole Genome Sequencing Market size was valued USD 2.23 billion in 2024 and is anticipated to reach USD 10.86 billion by 2032, at a CAGR of 21.9% during the forecast period.

Integrated Food Ingredient Market

The global integrated food ingredient market was valued at USD 3.46 billion in 2024 and is projected to reach USD 6.13 billion by 2032, growing at a CAGR of 7.4% during the forecast period.

Thyroid Gland Disorders Treatment Market

Thyroid Gland Disorder Treatment Market size was valued USD 2.49 billion in 2024 and is anticipated to reach USD 3.14 billion by 2032, at a CAGR of 2.98% during the forecast period.

Teleradiology Market

The teleradiology software market size was valued at USD 5.64 billion in 2024 and is anticipated to reach USD 10.68 billion by 2032, at a CAGR of 8.3 % during the forecast period.

Medical Mobility Aids Market

The Medical Mobility Aids Market was valued at USD 9.03 billion in 2024 and is projected to reach USD 15.75 billion by 2032, growing at a CAGR of 7.2% during the forecast period.

Anterior Lumbar Interbody Fusion Market

The Anterior Lumbar Interbody Fusion (ALIF) Market was valued at USD 10.93 billion in 2024 and is expected to reach USD 16.9 billion by 2032, growing at a CAGR of 5.6% during the forecast period.

Bacteriological Testing Market

The Global Bacteriological Testing Market size was valued at USD 16,553.3 million in 2018, rising to USD 24,798.7 million in 2024, and is anticipated to reach USD 44,396.7 million by 2032, at a CAGR of 7.61% during the forecast period.

U.S. Bacteriological Testing Market

The U.S. Bacteriological Testing Market size was valued at USD 3,333.84 million in 2018, reaching USD 4,877.10 million in 2024, and is anticipated to achieve USD 8,453.13 million by 2032, at a CAGR of 7.13% during the forecast period.

Elderberry Supplements Market

The Global Elderberry Supplements Market size was valued at USD 304.20 million in 2018 to USD 470.33 million in 2024 and is anticipated to reach USD 868.71 million by 2032, at a CAGR of 7.42% during the forecast period.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample